Orchestra BioMed (OBIO) CFO receives 181,000 restricted stock units grant

Rhea-AI Filing Summary

Taylor Andrew Lawrence reported acquisition or exercise transactions in this Form 4 filing.

Orchestra BioMed Holdings Chief Financial Officer granted 181,000 RSUs. On February 12, 2026, CFO Andrew Taylor received an award of 181,000 restricted stock units, each representing a right to one share of common stock at a grant price of $0. The RSUs vest in four equal 25% installments at 18, 24, 30 and 36 months after February 12, 2026, contingent on his continued service. Following this grant, he beneficially owns 632,493 shares of common stock directly.

Insider Trade Summary

Net Buyer: 181,000 shares

Net Buy 1 txn

Insider Taylor Andrew Lawrence

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, par value $0.0001 per share	181,000	$0.00	$0.00

Holdings After Transaction: Common Stock, par value $0.0001 per share — 632,493 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 25% of the shares will vest 18 months after February 12, 2026 (the "Issue Date"), (ii) 25% of the shares will vest 24 months after the Issue Date, (iii) 25% of the shares will vest 30 months after the Issue Date and (iv) 25% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/13/2026 - 05:01 PM Learn about SEC filing dates

FAQ

What insider transaction did Orchestra BioMed (OBIO) report for its CFO?

Orchestra BioMed reported that its Chief Financial Officer, Andrew Taylor, received an award of 181,000 restricted stock units. Each RSU represents a contingent right to one share of common stock, subject to a multi-year vesting schedule tied to continued service.

How many Orchestra BioMed (OBIO) shares are tied to the CFO’s new RSU grant?

The new award covers 181,000 restricted stock units, each linked to one share of common stock. If fully vested and settled, the grant would deliver 181,000 shares to the CFO, assuming all service conditions are met over the vesting period.

What is the vesting schedule for the Orchestra BioMed (OBIO) CFO’s 181,000 RSUs?

The 181,000 RSUs vest over three years in four equal 25% installments. Vesting occurs 18, 24, 30, and 36 months after February 12, 2026, provided the Chief Financial Officer remains in continuous service through each scheduled vesting date.

At what price were the Orchestra BioMed (OBIO) CFO’s RSUs granted?

The restricted stock units were granted at a reported price of $0 per unit, reflecting that they are an equity award rather than a cash purchase. Value realization for the Chief Financial Officer depends on future share deliveries as the RSUs vest over time.

How many Orchestra BioMed (OBIO) shares does the CFO own after this RSU award?

After the reported RSU grant, the Chief Financial Officer beneficially owns 632,493 shares of Orchestra BioMed common stock. This figure reflects his direct ownership following the award and is disclosed as part of the Form 4 insider ownership reporting requirements.

What type of Form 4 transaction code applies to the Orchestra BioMed (OBIO) CFO’s award?

The transaction is coded as “A” on Form 4, indicating a grant, award, or other acquisition of securities. This confirms the CFO received the 181,000 restricted stock units as compensation rather than buying them in an open-market or cash transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Andrew Lawrence

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	02/12/2026		A		181,000(1)	A	$0	632,493	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 25% of the shares will vest 18 months after February 12, 2026 (the "Issue Date"), (ii) 25% of the shares will vest 24 months after the Issue Date, (iii) 25% of the shares will vest 30 months after the Issue Date and (iv) 25% of the shares will vest 36 months after the Issue Date, subject to the Reporting Person's continuous service through such dates.

	/s/ Andrew Taylor	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.